Memphasys Limited (ASX:MEM)

Market Cap	5.95M
Revenue (ttm)	531.98K
Net Income (ttm)	-4.94M
Shares Out	1.98B
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	890,000
Average Volume	979,810
Open	0.0030
Previous Close	0.0030
Day's Range	0.0030 - 0.0040
52-Week Range	0.0030 - 0.0110
Beta	0.40
RSI	42.72
Earnings Date	Aug 29, 2025

About Memphasys

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company primarily develops Felix, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid oxidative stress assay; and AI-Port. In addition, the company offers ambient temperature storage product for human sperm. Memphasys Limited was incorporated in 2006 and is based in Homebush,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 24
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MEM

Financial Performance

In 2025, Memphasys's revenue was 531,980, a decrease of -51.19% compared to the previous year's 1.09 million. Losses were -4.94 million, 11.3% more than in 2024.